Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Will Present Brilinta Panel With Alternative Explanation For Negative U.S. Data

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA reviewers discredit AstraZeneca's suggestion that higher doses of aspirin explain ticagrelor's discordant results for U.S. versus overall trial participants - but also offer an alternative reason for the findings.

You may also be interested in...



AstraZeneca's Brilinta Approved With Aspirin Warning

Anti-platelet ticagrelor carries a boxed warning that concomitant aspirin dose must be limited to 100 mg/day, a departure for U.S. prescribers accustomed to high-dose aspirin therapy.

AstraZeneca's Brilinta Approved With Aspirin Warning

Anti-platelet ticagrelor carries a boxed warning that concomitant aspirin dose must be limited to 100 mg/day, a departure for U.S. prescribers accustomed to high-dose aspirin therapy.

Brilinta "Complete Response" Letter Suggests FDA Unswayed On U.S. Efficacy

Agency asks AstraZeneca for additional analyses of data from the 18,000-patient PLATO study, in which no benefit of ticagrelor over clopidogrel was seen in U.S. acute coronary syndrome patients.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070959

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel